These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35361730)

  • 21. Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer.
    Feng X; Meng X; Tang D; Guo S; Liao Q; Chen J; Xie Q; Liu F; Fang Y; Sun C; Han Y; Ai J; Li K
    Cancer Pathog Ther; 2024 Jan; 2(1):38-49. PubMed ID: 38328710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
    Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
    BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A high interferon gamma signature of CD8
    Li S; Li K; Tian F; Li H; Xia Q; Li T; Dong B; Li D; Yu J; Zhang J; Wang L; Zhang C; Xu S; Zhao Y; Liu Y
    Front Immunol; 2022; 13():1056144. PubMed ID: 36685525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
    He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
    Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
    Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells.
    He Y; Yang D; Lin X; Zhang J; Cheng R; Cao L; Yang L; Zhang M; Shi X; Jin X; Sun H; Sun H; Zang J; Li Y; Ma J; Nie H
    Front Immunol; 2024; 15():1412693. PubMed ID: 39076970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
    Christina Svensson M; Lindén A; Nygaard J; Borg D; Hedner C; Nodin B; Leandersson K; Jirström K
    Oncoimmunology; 2021 May; 10(1):1921443. PubMed ID: 34104541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
    Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
    Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.
    van Wilpe S; Sultan S; Gorris MAJ; Somford DM; Kusters-Vandevelde HVN; Koornstra RHT; Gerritsen WR; Simons M; van der Heijden AG; de Vries IJM; Mehra N
    Cancer Immunol Immunother; 2023 Jan; 72(1):137-149. PubMed ID: 35771253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
    Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
    BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased intratumoral Foxp3 Tregs and increased dendritic cell density by neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer.
    Hu M; Li K; Maskey N; Xu Z; Peng C; Wang B; Li Y; Yang G
    Int J Clin Exp Pathol; 2014; 7(8):4685-94. PubMed ID: 25197340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
    Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
    Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.
    Wang JB; Gao YX; Ye YH; Zheng QL; Luo HY; Wang SH; Zhang T; Jin QW; Zheng CH; Li P; Lin JX; Chen QY; Cao LL; Yang YH; Huang CM; Xie JW
    Theranostics; 2024; 14(7):2915-2933. PubMed ID: 38773976
    [No Abstract]   [Full Text] [Related]  

  • 37. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
    Liang Y; Yu M; Zhou C; Zhu X
    Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.
    Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
    J Immunol Res; 2016; 2016():4757405. PubMed ID: 27777963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
    BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
    Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
    Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.